JonesTrading analyst Soumit Roy maintained a Buy rating on Adicet Bio (ACET – Research Report) today and set a price target of $4.00.
Soumit Roy’s rating is based on the promising potential of Adicet Bio’s innovative cell therapy programs. The company is advancing two Phase 1 programs targeting lupus nephritis and systemic lupus erythematosus, as well as renal cancer, with initial data expected in the latter half of 2025. These programs utilize unique CAR γδ T cell therapies, which differentiate Adicet from its peers primarily targeting CD19, thereby opening new opportunities in the cell therapy space.
Additionally, Adicet Bio’s receipt of Fast Track Designation for its ADI-001 therapy in refractory systemic lupus erythematosus and systemic sclerosis highlights the potential for accelerated development and approval. The company’s strategic focus on expanding its trial to include other autoimmune conditions further underscores its commitment to addressing unmet medical needs, which could enhance its market position and drive future growth.
Roy covers the Healthcare sector, focusing on stocks such as Precision BioSciences, Chimerix, and Day One Biopharmaceuticals. According to TipRanks, Roy has an average return of -25.5% and a 18.18% success rate on recommended stocks.
In another report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $8.00 price target.